$93.26
3.16% day before yesterday
NYSE, May 16, 10:10 pm CET
ISIN
US7140461093
Symbol
RVTY

PerkinElmer Stock price

$93.26
-0.49 0.52% 1M
-16.21 14.81% 6M
-18.35 16.44% YTD
-15.20 14.01% 1Y
-53.53 36.47% 3Y
-0.06 0.06% 5Y
+40.91 78.15% 10Y
NYSE, Closing price Fri, May 16 2025
+2.86 3.16%
ISIN
US7140461093
Symbol
RVTY
Sector

Key metrics

Market capitalization $10.99b
Enterprise Value $13.18b
P/E (TTM) P/E ratio 36.87
EV/FCF (TTM) EV/FCF 25.26
EV/Sales (TTM) EV/Sales 4.76
P/S ratio (TTM) P/S ratio 3.97
P/B ratio (TTM) P/B ratio 1.46
Dividend yield 0.30%
Last dividend (FY24) $0.28
Revenue growth (TTM) Revenue growth 1.62%
Revenue (TTM) Revenue $2.77b
EBIT (operating result TTM) EBIT $424.38m
Free Cash Flow (TTM) Free Cash Flow $521.70m
Cash position $1.14b
EPS (TTM) EPS $2.53
P/E forward 38.07
P/S forward 3.86
EV/Sales forward 4.63
Short interest 6.08%
Show more

Is PerkinElmer a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,790 stocks worldwide.

PerkinElmer Stock Analysis

Unlock Scores for Free

Analyst Opinions

21 Analysts have issued a PerkinElmer forecast:

13x Buy
62%
7x Hold
33%
1x Sell
5%

Analyst Opinions

21 Analysts have issued a PerkinElmer forecast:

Buy
62%
Hold
33%
Sell
5%

Financial data from PerkinElmer

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
2,770 2,770
2% 2%
100%
- Direct Costs 1,313 1,313
1% 1%
47%
1,457 1,457
2% 2%
53%
- Selling and Administrative Expenses 415 415
3% 3%
15%
- Research and Development Expense 200 200
5% 5%
7%
842 842
4% 4%
30%
- Depreciation and Amortization 417 417
3% 3%
15%
EBIT (Operating Income) EBIT 424 424
12% 12%
15%
Net Profit 310 310
76% 76%
11%

In millions USD.

Don't miss a Thing! We will send you all news about PerkinElmer directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

PerkinElmer Stock News

Negative
Seeking Alpha
9 days ago
Revvity faces multiple headwinds including declining biotech funding, regulatory uncertainty, and reduced academic research budgets. Despite challenges, Revvity's Q1 results beat expectations and the company maintained full-year guidance. While I rate Revvity a buy, it faces some structural challenges longer-term.
Neutral
Business Wire
18 days ago
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced it will present at the following investor conferences: Bank of America Global Healthcare Conference 2025 Tuesday, May 13, 2025 9:20 a.m. PT - Max Krakowiak, senior vice president and chief financial officer Goldman Sachs 46th Annual Global Healthcare Conference Tuesday, June 10, 2025 8:00 a.m. ET - Prahlad Singh, presi...
Neutral
Seeking Alpha
20 days ago
Revvity, Inc. (NYSE:RVTY ) Q1 2025 Earnings Conference Call April 28, 2025 8:00 AM ET Company Participants Steve Willoughby - Senior Vice President, Investor Relations Prahlad Singh - President & Chief Executive Officer Max Krakowiak - Senior Vice President & Chief Financial Officer Conference Call Participants Patrick Donnelly - Citi Dan Brennan - TD Cowen Matt Sykes - Goldman Sachs Vijay Kuma...
More PerkinElmer News

Company Profile

PerkinElmer, Inc. engages in the provision of products, services, and solutions for diagnostics, food, environmental, life sciences, and applied markets. It operates through the following segments: Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment comprises of technologies that help life sciences researchers better understand diseases and develop treatments. The Diagnostics segment offers instruments, reagents, assay platforms, and software to hospitals, medical labs, clinicians, and medical research professionals to help improve the health of families. The company was founded by Richard Scott Perkin and Charles W. Elmer on April 19, 1937 and is headquartered in Waltham, MA.

Head office United States
CEO Prahlad Singh
Employees 11,000
Founded 1937
Website www.revvity.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today